Drake v. Bayer Healthcare LLC

CourtDistrict Court, S.D. California
DecidedJanuary 5, 2024
Docket3:22-cv-01085
StatusUnknown

This text of Drake v. Bayer Healthcare LLC (Drake v. Bayer Healthcare LLC) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Drake v. Bayer Healthcare LLC, (S.D. Cal. 2024).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 EDISON CORPUZ, individually and on Case No. 22-cv-1085-MMA (JLB) behalf of all others similarly situated, 12 et al., ORDER DENYING DEFENDANT’S 13 MOTION TO DISMISS FIRST Plaintiffs, AMENDED COMPLAINT 14 v. 15 [Doc. No. 70] BAYER CORPORATION, 16 Defendant. 17 18 19 20 21 22 Pending before the Court is Defendant Bayer Corporation’s (“Defendant”) motion 23 to dismiss Plaintiffs Edison Corpuz, Deniece Drake, and Deborah Bowling’s 24 (“Plaintiffs”) First Amended Complaint. Doc. No. 70. Plaintiffs filed an opposition, 25 Doc. No. 74, and Defendant replied, Doc. No. 77. The Court found the matter suitable 26 for determination on the papers and without oral argument pursuant to Federal Rule of 27 Civil Procedure 78(b) and Civil Local Rule 7.1.d.1. See Doc. No. 78. For the reasons set 28 forth below, the Court DENIES Defendant’s motion to dismiss. 1 I. BACKGROUND 2 This putative class action involves Defendant’s popular “One A Day” (“OAD”) 3 line of multivitamins. Doc. No. 69 (First Amended Complaint, the “FAC”) ¶¶ 1, 12. 4 Specifically, Plaintiffs’ FAC concerns Defendant’s OAD Natural Fruit Bites 5 Multivitamin products (the “Products”), including the following “four varieties: Men’s, 6 Women’s, Men’s 50+, and Women’s 50+.” Id. ¶ 1 n.1. Plaintiffs allege Defendant’s 7 “advertising and marketing campaign is false, deceptive, and misleading” because it 8 holds its Products out as “natural” even though they “contain non-natural, synthetic 9 ingredients.” Id. ¶¶ 1–2. 10 Plaintiff Corpuz filed his initial complaint on July 25, 2022, alleging a violation of 11 California’s Consumers Legal Remedies Act (“CLRA”), Cal. Civ. Code § 1750 et seq., as 12 his sole cause of action. Doc. No. 1. On October 5, 2022, Defendant moved to dismiss 13 Corpuz’s complaint under Federal Rule of Civil Procedure 12(b)(6). Doc. No. 22. On 14 February 28, 2023, the Court denied Defendant’s motion to dismiss, finding that Corpuz 15 alleged with sufficient plausibility that a reasonable consumer would likely be deceived 16 by the term “natural” used on Defendant’s Products. Doc. No. 26. In response to this 17 Order, Defendant filed an answer to Corpuz’s complaint on March 27, 2023. Doc. No. 18 32. 19 On August 15, 2023, while discovery was well underway, Corpuz and Defendant 20 filed a joint motion for leave to file an amended complaint, which the Court granted. 21 Doc. Nos. 65; 66. The FAC, which Plaintiffs filed on August 24, 2023, added two new 22 individual Plaintiffs—Drake and Bowling2—as well as two new causes of action for false 23 advertising under New York General Business Law §§ 349 and 350. See generally FAC. 24 In addition, Plaintiffs reallege a violation of the CLRA and include largely the same 25

26 1 Reviewing Defendant’s motion to dismiss, the Court accepts as true all facts alleged in the FAC and 27 construes them in the light most favorable to Plaintiffs. See Snyder & Assocs. Acquisitions LLC v. United States, 859 F.3d 1152, 1157 (9th Cir. 2017). 28 1 factual allegations as in Corpuz’s original complaint, which the Court further detailed in 2 its February 28, 2023 Order denying Defendant’s motion to dismiss. See Corpuz v. 3 Bayer Corp., No. 22-CV-1085-MMA (JLB), 2023 WL 2292579, at *1–2 (S.D. Cal. Feb. 4 28, 2023). The Court incorporates that discussion by reference here. 5 In the instant motion, Defendant again moves to dismiss Plaintiffs’ FAC pursuant 6 to Federal Rule of Civil Procedure 12(b)(6). See Doc. No. 70. 7 II. LEGAL STANDARD 8 Under Rule 12(b)(6),3 a district court must dismiss if a claim fails to state a claim 9 upon which relief can be granted. To survive a Rule 12(b)(6) motion to dismiss, the 10 claimant must allege “enough facts to state a claim to relief that is plausible on its face.” 11 Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). A claim is facially plausible when 12 the plaintiff pleads facts that “allow the court to draw the reasonable inference that the 13 defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 14 (2009) (citation omitted). There must be “more than a sheer possibility that a defendant 15 has acted unlawfully.” Id. While courts do not require “heightened fact pleading of 16 specifics,” a claim must be supported by facts sufficient to “raise a right to relief above 17 the speculative level.” Twombly, 550 U.S. at 555, 570. 18 III. REQUEST FOR JUDICIAL NOTICE 19 As an initial matter, Defendant asks the Court to take judicial notice of several 20 exhibits in support of its motion to dismiss. See Doc. No. 70-2. The Court finds that it 21 need not determine if judicial notice is appropriate in this case because Defendant’s 22 exhibits do not bear on the Court’s analysis below. As such, the Court DENIES 23 Defendant’s request for judicial notice. 24 /// 25 26 27 28 1 IV. DISCUSSION 2 “To prevail on their consumer fraud claims under New York and California 3 law, Plaintiffs must establish that [Defendant’s] allegedly deceptive advertisements were 4 likely to mislead a reasonable consumer acting reasonably under the circumstances.” 5 Fink v. Time Warner Cable, 714 F.3d 739, 741 (2d Cir. 2013) (per curiam) (citations 6 omitted). “This is not a negligible burden.” Moore v. Trader Joe’s Co., 4 F.4th 874, 7 882 (9th Cir. 2021). Plaintiffs must allege “more than a mere possibility” that the 8 “label might conceivably be misunderstood by some few customers viewing it in an 9 unreasonable manner.” Id. (quoting Ebner v. Fresh, Inc., 838 F.3d 958, 965 (9th Cir. 10 2016)). Instead, Plaintiffs must plausibly show that “a significant portion of the 11 general consuming public or of targeted consumers, acting reasonably in the 12 circumstances,” would share their expectations. Id. (quoting Ebner, 838 F.3d at 965). 13 In its previous Order, the Court denied Defendant’s Rule 12(b)(6) motion to 14 dismiss Plaintiff’s sole cause of action under the CLRA. See Doc. No. 26. Significantly, 15 the Court rejected Defendant’s argument that no reasonable consumer could be confused 16 by the inclusion of the word “natural” on its Products’ labels. Id. at 7–9. In addition, the 17 Court ruled that the Ninth Circuit’s general prohibition on using an ingredient list to 18 correct a misleading label applied because “Plaintiff sufficiently allege[d] that 19 [Defendant’s] Products’ labels are deceptive rather than ‘ambiguous.’” Id. at 9–10. In 20 the instant motion to dismiss, Defendant renews its arguments but now relies on the 21 Ninth Circuit’s recent decision in McGinity v. Procter & Gamble, 69 F.4th 1093 (9th Cir. 22 2023) for support. Specifically, Defendant argues that the facts of this case are “near- 23 identical” to McGinity and that McGinity now “makes clear that Plaintiffs’ alleged 24 interpretation [of the word natural on the Products’ labels] is unreasonable and 25 implausible.” Doc. No. 70-1 sat 11. The Court disagrees. 26 Defendant incorrectly argues that McGinity “drew a clear distinction between 27 products that use the terms ‘nature’ or ‘natural’ and products that claim to be ‘100% 28 natural’ or ‘all natural.’” Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Fink v. Time Warner Cable
714 F.3d 739 (Second Circuit, 2013)
Ebner v. Fresh, Inc.
838 F.3d 958 (Ninth Circuit, 2016)
Sean McGinity v. the Procter & Gamble Company
69 F.4th 1093 (Ninth Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
Drake v. Bayer Healthcare LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/drake-v-bayer-healthcare-llc-casd-2024.